Showing posts with label androgens. Show all posts
Showing posts with label androgens. Show all posts

Saturday, May 11, 2013

Androgen 3-Some: BPA Exposure & Free Testosterone in Men. TRT Good For the Prostate. DHT, Alopecia (Hair Loss) & Monascus Fermentation. Plus: Mycotoxins in GCB Supps

Coffee and green coffee bean extracts are by no means the only way by which you are exposed to mycotoxins. Corn, for example, is likewise a favorite for the toxic mold. The same goes for almost all other grains. Common routes of exposure are, amongst others cereals, breads, wines, and even mils and meats (of swine ad turkey, not chicken; Duarte. 2010)
36%, 32%, 10%, and 16% these are the SuppVersity Figures of the week and the percentages of green coffee bean supplements (remember the chlorogenic acid news in Thursday's installment of the Science Round-Up) that were contaminated with Ochratoxin A, ochratoxin B, fumonisin B1 and mycophenolic acid, respectively.
"Mycotoxins occurred in the following concentration ranges: ochratoxin A: 2.7–136.9 µg/kg, ochratoxin B: 3.5–20.2 µg/kg, fumonisin B1: 110.0–415.0 µg/kg, mycophenolic acid: 43.1–395.0 µg/kg." (Vaclavi. 2013)
These poisonous substances are produced by fungi that form during (inproper) storage and are suspected to inhibit protein synthesis, damage macrophage systems, inhibit particle clearance of the lung, and increase sensitivity to bacterial endotoxins... ah, I almost forgot ochratoxins also wreak havoc on your hormones (Frizzell. 2013).

So far for the bad news, now the good one: According to the researchers calculations even with most contaminated of the 50 products they the average consumer who adheres to the suggested dosing protocol will still be well within the tolerable weekly intake (TWI) of 120 ng/kg body weight per week and tolerable daily intake (TDI) of 2000 ng/kg body weight per day for ochratoxin A and fumonisin B1, respectively (these values were estimated by the EU Scientific Committee on Food (SCF) and the European Food Safety Authority (EFSA) - corresponding values of the "well-meaning" FDA or any other US government agencies are - as usual - not available).

Let's get to our androgen threesome

  • SuppVersity readers know: Tea is not only good for your prostate (learn more), it can also help you lose weight (read more)
    Testosterone replacement improves prostate issues (Ko. 2013) -- Contrary to what common "wisdom" will tell you scientists from the Yeungnam University College of Medicine in Korea can tell you that the 17 out of  46 patients who suffered from lower urinary tract symptom before they underwent TRT using intramuscular injection of 3 months bases injection of testosterone 1,000 mg undecanoate over a year achieved significant improvements (decrements) on the International Prostate Symptom Score (IPSS).

    Needless to say that "[d]uring the median follow up of 15.1 months, no patients experienced urinary retention, BPH-related surgery, or admission for urinary tract infection".
  • BPA and low testosterone, you better know what to look at (Zhou. 2013) -- Talking about testosterone, there is finally some relatively reliable human data on the effects of BPA exposure on the hormone levels in men.
    Figure 1: Relative difference in free androgen index (FAI), androstenedione (AD), free testosterone (FT), SHBG, inhibin (INB), prolactin (PRL), follicle stimulating hormone (FSH), estrogen (E2) an total testosterone (T);  comparing the men with to the men without workplace exposure in the Zhou study
    As you can see in figure 1 the effects would go unnoticed, if you do not test for free hormones, but just checked the amount of total testosterone. How you can recognize that from the data? Well, the figures above the bars are the p-values. All that are >0.5 would suggest that this effect is statistically non-significant, so that every study not looking at things like the free androgen index (FAI) or the free testosterone levels (FT) will miss the 15% and 10% reduced levels of the latter and conclude: That it does not make a difference, if your serum contains 3.198 or 0.276mg/L as it was the case in the exposed and non-exposed subjects in this study from the Shanxi Medical University, because BPA won't harm you anyway.
  • The fermented solution to all problems androgen?  (Chiu. 2013) Monascus bacteria that is used to ferment red mold rice, a traditional spice that is consumed throughout Asia could prevent androgenetic alopecia, benign prostate hyperplasia and prostate cancer.
    Figure 2: Changes in testosterone an DHT mice on TRT (control) w/w-out 0.2 & 0.5% Monascus extract in chow, corresponding images of the stained slices from the prostate and hair loss compared to standard treatment with finasteride (Chiu. 2013)
    The results of a recent study from the Department of Environmental and Occupational Health at the National Cheng Kung University Medical College clearly suggest that the way in which a monascus extract suppressed baldness in male B6CBAF1/j mice 
      Learn how to modulate DHT/T naturally.
    • decreased PSA levels  
    The effect was dose-dependent and was observed with 0.5-3% of the extract in the rodent diets. While it is not unlikely that the results will translate into human studies, it should be obvious that at least for the >0.5% doses, supplementation will be necessary.

    Irrespective of these latest study results, previous research indicates that Monascus-fermented products have many functional secondary metabolites, including monacolin K, citrinin, ankaflavin, and monascin and these have been shown to possess anti-inflammatory, antioxidative, cholesterol-lowering effect, and antitumor activities. Probably all of you will be familiar with at least one of them: Red Yeast Rice, the natural statin. And if you are not into spices or extracts, there are also other foods and even wines that are fermented with Monascus.

That's it for today: I know ladies, with today's focus on the male hormones, I owe you (big time?). But don't worry, there are also a couple of Facebook News, you may be interested in
  • Suggested read: "Carbohydrate Shortage in Paleo Land" (read more)
    "Oldie but goldie: T3, rt3 and carbohydrate intake in hyper- and eucaloric scenarios - Something worth considering for those constantly battling low T3 an high rT3 levels (read more)
  • Omnipresence of "healthy" Subway sandwiches correlates w/ obesity rates - "Countries with the highest density of Subway restaurants such as the USA (7.52 per 100,000) and Canada (7.43 per 100,000) also tend to have a higher prevalence of obesity in both men (31.3% and 23.2%, respectively) and women (33.2% and 22.9%, respectively)." (read more)
  • Understanding the neurological side effects of statin drugs - US scientists observed unusual swellings within neurons, which the team has termed the "beads-on-a-string" effect (read more)
  • DHEA supplementation at 25gm/day to restore female fertility - A recent study from Turkey would suggest that this could actually work (read more)
If that's still not enough, come back tomorrow for another serving of the latest news from the realms of exercise, nutrition and health sciences, here at the SuppVersity! In the mean time, enjoy your weekend, everone!
References:
  • Chiu HW, Chen MH, Fang WH, Hung CM, Chen YL, Wu MD, Yuan GF, Wu MJ, Wang YJ. Preventive effects of monascus on androgen-related diseases: androgenetic alopecia, benign prostatic hyperplasia, and prostate cancer. J Agric Food Chem. 2013 May 8;61(18):4379-86.  
  • Duarte SC, Pena A, Lino CM. Ochratoxin a in Portugal: a review to assess human exposure. Toxins (Basel). 2010 Jun;2(6):1225-49. doi: 10.3390/toxins2061225. Epub 2010 Jun 1. Review. 
  • Frizzell C, Verhaegen S, Ropstad E, Elliott CT, Connolly L. Endocrine disrupting effects of ochratoxin A at the level of nuclear receptor activation and steroidogenesis. Toxicol Lett. 2013 Mar 13;217(3):243-50.  
  • Ko YH, Moon du G, Moon KH. Testosterone replacement alone for testosterone deficiency syndrome improves moderate lower urinary tract symptoms: one year follow-up. World J Mens Health. 2013 Apr;31(1):47-52.
  • Vaclavik L, Vaclavikova M, Begley TH, Krynitsky AJ, Rader JI. Determination of Multiple Mycotoxins in Dietary Supplements Containing Green Coffee Bean Extracts Using Ultrahigh-Performance Liquid Chromatography–Tandem Mass Spectrometry (UHPLC-MS/MS). Journal of Agricultural and Food Chemistry. May 2013 [ahead of print].
  • Zhou Q, Miao M, Ran M, Ding L, Bai L, Wu T, Yuan W, Gao E, Wang J, Li G, Li DK. Serum bisphenol-A concentration and sex hormone levels in men. Fertil Steril. 2013 May 4.

Sunday, January 22, 2012

Intermittent Thoughts: Dihydrotestosterone (DHT) - Bigger, Stronger, Faster or just Balder, Fatter and Unhealthier?

Image 1: The ancient Greek ideal of the male body has probably more to do with DHT than the freaky physiques of today's IFBB Pro bodybuilders.
I guess after the revelations about the importance of estrogen in the process of skeletal muscle hypertrophy in the last installment of the Intermittent Thoughts you will probably be eager to hear what its male counterpart dihydrotestosterone (DHT), is able to do... I mean, with DHT being the male hormone par excellence it is only reasonable to assume that its effects on skeletal muscle mass and strength, two characteristic features of the male persuasion, must be significant, right? Before we are going to address this vitally important questions, let's briefly take a look at what the dihydrotestosterone actually is.

DHT the hormone to which testosterone is just another prohormone

Similar to estrogen, DHT (exact name 17β-hydroxy-5α-androstan-3-one) is a testosterone metabolite. The process by which your body (male and female, btw.) generates this powerful androgen, the receptor-affinity of which is about 3x-10x higher than that of testosterone (depending on which source you cite and which assay the researchers used; for more detailed data on receptor binding, check out my previous blogpost "Beyond Vida's Book") is called 5-alpha reductase (5-ar). In the course of the "reduction" process one of hitherto three identified mammalian isoforms of the 5-alpha reductase enzyme (3-oxo-steroid-4-ene dehydrogenase). Of these three isoforms, which catalyze the reduction process, type III (predominantly) and type I (to a lesser extend) are expressed in human skeletal muscle (cf. Yarrow. 2011)...
Illustration 1: (1) Testosterone (either preformed or locally formed from DHEA) arrives at the target tissue, (2) is reduced to DHT by one out of three locally expressed reductase enzymes and (3) either acts intracrine, i.e. right inside the cell, where it was formed or is released into circulation.
I do not want to lose myself in too many details at this point, but a rough grasp of the local reduction of testosterone and the subsequent intracrine (meaning right where the hormone is created, cf. illustration 1) effects of DHT is of paramount importance to understand some of the initially counter-intuitive effects of DHT, you are going to read about in the following paragraphs.

"DHT makes you strong bro!" - correct!

At least for those of you who have been on some of the bulletin boards, where people discuss the effects of various androgenic compounds, the first statements that pop into your mind, when you hear the three letters D, H and T, could be "brutal strength gains", "hit new personal records on each lift" or "doubled my bench within 2 weeks". And although I suppose that statements such as the latter lack any empirical basis, the broscientitific evidence that DHT and DHT-like designer steroids exert profound effects on muscle strength cannot be denied.

In this context, the results of a 2010 study from the Biomedical and Clinical Sciences Research Institute at the School of Medicine, Health Policy and Practice of the University of East Anglia in Norwich, UK, is of particular significance (Hamdi. 2010). Using isolated extensor digitorum longus (EDL, a mainly fast twitch muscle in adult mice) and extensor digitorum longus (EDL, a mainly fast twitch muscle in adult mice) muscles from male and female mice, M.M. Hamdi and G. Mutungi established that the strength promoting effects of DHT are mediated mainly via the ERK, i.e. the extracellular signal-regulating kinase (also known as MAPK), pathway and thusly in a non-androgen receptor mediated way.
Figure 1: Maximal isometric force production in slow an fast twitch fibers after incubation with 630pg/ml DHT; data expressed relative to initial isometric force production P0 (data calculated based on Hamdi. 2010)
As the data in figure 1 goes to show, incubation of isolated rat myofibers with 630pg/ml androstanolone (17β-hydroxy-5α-androstan-3-one, DHT) increased the isometric force (P0 = 100%) of the fast twitch muscle fibers in the EDL from both male and female mice by ~30%. If we take a look at the SuppVersity's Motto  "Where Bro- and Pro-Science Meet in the Spirit of True Wisdom", this is thusly one of the (as of late rare) occasions, where bro- and pro-science actually "meet", not "clash", in the "Spirit of True Wisdom".

DHT works via the MAPK pathway and not via the androgen receptor

Without the "pro"-aspect of science we would yet not know that it this is neither a androgen receptor mediated action (as the use of a DHT-inhibitor did not block the effects) nor a downstream effect of IGF-1 (the inhibition of which by co-incubation with an IGR-R inhibitor left the effects similarly unchanged), but a direct effect of the DHT induced increase in ERK-1/2 phosphorylation and the subsequent accumulation of myosin light chain in the DHT treated rodent muscle:
Our hypothesis is that DHT activates the epidermal growth factor receptor (EGFR), either directly or indirectly, and this leads to an increase in the phosphorylation of ERK1/2. The activated ERK1/2 then phosphorylates MLCK which in turn phosphorylates the 20 kDa RMLCs and this increases force production in fast twitch fibres but decreases it in slow twitch fibres. (Hamdi. 2010)
In that, it is not really important that you understand all the intermediate steps which eventually lead to the increase in force production. What is important though is the hypothesis that the changes, you are seeing in figure 2 are not mediated via the androgen receptor, which were equally distributed in both the slow- and fast-twitch fibers in the study at hand - this is particularly noteworthy, because after all DHT is the androgen per se.

Figure 2: Changes (a.u.) in phosphorylated ERK-1/2 and myosin light chain content of slow twitch and fast twitch muscle fiber treated with either DHT or testosterone propionate; * p < 0.05 (data calculated based on Hamdi. 2010)
The experiments also revealed that, despite the increase in p-ERK-1/2 in the slow-twitch muscle fibers, testosterone treatment did not induce similar changes in myosin light chain content like DHT. In view of the fact that the scientists have used female DGL and soleus muscle fibers for this experiment to minimize the local reduction of DHT to testosterone and isolate the effects of DHT, it should also be stated that the last-mentioned effects on slow-twitch fiber ERK-1/2 phosphorylation may well be a downstream effect of the aromatization of testosterone to estrogen (cf. "Estrogen: Friend or Foe of Skeletal Muscle Hypertrophy").

Against that background it is actually quite astonishing that a series of rodent studies which were conducted by scientists from Japan (Aizawa. 2010; 2011) found statistically significant increases in intra-muscular DHT in response to an endurance type of exercise. If you add to that the results of a 2008 human study by Hawkins et al. (Hawkins. 2008), which found a similar increase in systemic DHT (and SHBG) levels in 102 sedentary men (ages 40-75 yr) who were randomly assigned to a 12-month aerobic exercise intervention, while DHT levels did not budge in a 2008 study by Vingren et al. (Vingren. 2008), which used a resistance training protocol, this raises the question whether our current understanding of the strength promoting intracrine effects of DHT is not only part of a larger picture, which would be characterized by distinct intra-, auto-, para- and endocrine effects of DHT on skeletal muscle and other exercise related physiological functions.

The litmus test: Does DHT "build muscle"?

The absence of increased levels of DHT in response to strength training as well as the fact that the increase in myosin light chain is at best "facilitative" to building bigger already suggest that, with respect to its "muscle-building effect", your most potent androgen is somewhat of a non-starter... let me give you a three of the rare examples, where scientists even dared to administer DHT to their study participants, to substantiate (not prove) this hypothesis:
  • in 1992, Marin et al. found that 3 months of transdermal DHT administration to middle-aged obese men increased muscle strength and diameter of type II muscle fibers, albeit to a lesser extent than
    testosterone administration
    (Marin. 1992);
     
  • in a 3 month trial using transdermal DHT Ly et al  found a reduction in body fat mass and improved isokinetic knee flexion strength of the dominant leg, but no improvements in lean body mass, knee extension strength, or shoulder flexion/extension strength in hypogonadal elderly men (Ly. 2001);
     
  • in 2010, Idan et al. conducted a trial on the effects of DHT administration on prostate growth in 114 healthy men over 50 and found neither beneficial nor negative effects on prostate growth (please understand that I will not address the prostate issue in detail, as it is not directly related to the topic at hand and would require a whole installment of its own) and a very modest increase in lean mass (2.4%) in response to 70mg DHT gel for 2 years (!)
Now, if you take a look at these examples and compare that to what you know about the muscle-building effects of testosterone, it should be obvious why most "chemical athletes" (i.e. steroid users) take 5-ar inhibitors like finasteride when they are "on" high doses of testosterone. Since the latter will reduce the circulating levels of DHT by "only" 50% this practice allows them to keep any unwanted DHT-related androgenic side effects (which are going to occur when you reach supra-physiological DHT levels) at bay, while still having enough 5-alpha reductase activity to benefit from the highly appreciated effects on muscle strength.
Note: Contrary to finasteride, which is highly selective for the type II isoform of the 5-ar enzyme, dustasteride, which has been found to reduce circulating DHT levels by >90% is a pan-5-ar inhibitor. It is thusly no wonder that 0.5mg/day of dustasteride prevented the increase in lean mass in female-to-male transsexuals who were treated with 1,000mg testosterone-undeconate for 54 weeks (Meriggiola. 2008).
Although testosterone and not DHT appears to be the major hormonal driving force of actual increases in muscular size (not strength!), the results of the Meriggiola study, where the total (>90%) blockade of all three of the 5-ar isoforms by dustasteride (see red box, above) inhibited the muscle-building effects of 1,000mg testosterone-undeconate clearly suggest that the reduction of at least small amounts of testosterone to dihydrotestosterone is a necessary prerequisite for the testosterone-induced increases in lean muscle mass. Whether a critical threshold as for circulating DHT levels exists, or whether it was the dustasteride induced blockade of the local reduction of testosterone to DHT by 5-ar type III right in the skeletal muscle that was responsible for this effect will yet have to be established in future studies.

High serum DHT = lower chance of alopecia! High local 5-ar = hair loss, though.

Image 2: Is your hair line receding? Could be DHT, but local not systemic! In young men high DHT levels correlate with full hair, in older men the local increase in 5-ar or the and the reduction in SHBG can elevate DHT beyond a healthy threshold.
Now muscle is obviously not the only thing you want... and when it comes to DHT, hair, respectively the loss of the latter, obviously is the first thing that comes to mind. Notwithstanding that it is an established fact that bathing your hair follicles in excess amounts of dihydrotestosterone will eventually kill them, you may be surprised to hear that a 1992 paper by Knussmann et al. (Knussmann. 1992) showed that contrary to common believe the correlation between allopecia and serum DHT levels in the 110 healthy young men in their study is a negative one (r = -.25, p < 0.01). Yet although the same is true for total testosterone (r = -.25, p < 0.01), the correlation between the ratio of free / total testosterone (T_free/T_total) is positive and statistical significant (r = .02; p < 0.05)!

Now, how can that be? Is it testosterone that is "shaving your head from within?" - well, in a way it is, but most probably due to its local conversion to DHT (I hope by now you understand, why I stressed this factor in the introduction). Contrary to bound testosterone, which cannot be reduced by the 5-ar reductase enzymes in your scalp, the free testosterone can and will thusly - as a prohormone - do its bit to the thinning of your hairline:
[...] DHT in the hair follicle is thought to lead to hypoplasia of the scalp follicle, and a higher formation of testosterone metabolites was observed in the scalp of bald men as compared to hair obtained from nonbalding men. Yet we found a relationship, not between the disposition to balding and the ratio DHT/T, but between the diposition to balding and T_free/T_total. An elevated rate of dissociation from the binding globulin fits in well with the findings of Cipriani et al. (1983) that men with androgenic alopecia exhibit a significant reduction in sex hormone binding globulin (the same is true for bald-headed women). (Knussmann. 1992)
The overall increase in both aromatization and 5-a reduction with age, as well as the tissue specific expression of those enzymes thusly explains why your men begin losing their hair, as they get older although their total androgen levels begin to decline. A similar pattern, i.e. decreased SHBG levels and consequently increases in local 5-a reduction are implicated in female androgenic alopecia, as well (De Villez. 1986).
Note: If you want to judge your serum DHT levels by your body hair, the most prudent way to do so would be look at your legs. While the correlation (r = .16) Knussmann et al. found for DHT, alone, was not statistically significant, it was still the best indicator for "high" DHT levels.
Now, if we assume you have full hair and your legs have some resemblance to those of a bear (an unrealiable indicative of "high" DHT levels), does that predispose you to an increase in visceral body fat, as some sources on the Internet would have it? I mean, designer steroids that are structurally related to DHT are not particularly known for their obesogenic effect. They rather seem help their (ab-)users to lean out pretty rapidly, so the last question I will address in this installment of the Intermittent Thoughts will be ...

If testosterone helps you to lean out, will DHT make you fat?

To answer that I want to go back to the study, I presented in Friday's SuppVersity post on how eccentric training is able to recruit mesenchymal stem cells for muscular repair / hypertrophy. From either this post or the discussion of the underlying mechanisms by which testosterone works its muscle building, fat burning magic (cf. "Understanding the Big T"), you should remember that those pluripotent stem cells are unfortunately capable of becoming fat cells, as well. Luckily, dihydrotestosterone, the "big brother" of the "big T" shares testosterones anti-differential effect on pre-adipocytes (Singh. 2003).
Unfortunately, though, DHT does not prevent their proliferation (i.e. the generation of new pre-adipocytes; cf. Gupta. 2008). Instead, gene assays suggest that it stimulates all aspects of adipocyte metabolism, i.e. the beneficial ones like glycolosis (helps blood sugar management) and lipolysis (helps getting the fat out of the adipose tissue) and not (generally) beneficial ones as the production of fatty acids and triacylglyceroles, cell proliferation and differentiation (Bolduc. 2004).

Whether there is an overall negative effect of "normal" DHT levels on visceral fat, as it is sometimes suggested (esp. in the "lay press" = Internet ;-) appears however questionable. After all, Vandenput et al. (Vandenput. 2007) have shown that not DHT, but rather androstane-3 α,17-β-diol-17-glucuronide (17G), one of its metabolites correlates with visceral adiposity in healthy young men (r = 0.16; p < 0.05).
Figure 3: Correlation of the bioactive androgens (total and free testosterone and DHT) with DXA-measurements of body fat in different compartments; data obtained from n = 1068 young men (data adapted from Vandenput. 2007)

Serum DHT levels, on the other hand, showed the strongest negative correlation with total body fat, total body fat (% total mass), arm fat, leg fat and trunk fat of all three measured androgens (cf. figure 3) and was a close second to total testosterone as far as its negative, i.e. diminishing, effects on central fat distribution is concerned (r = -0.07; p <0.05).
Note: In view of the fact that, as of late, leptin has become a focus of attention even for the average person trying to lose weight, it might be of interest that there were statistically significant negative correlations (r = -0.23 and r = -0.25; young vs. elderly) in both study groups.
Interestingly, things look somewhat different for the 1001 elderly study participants. The pattern that emerges here should remind you of the previously discussed allopecia issue. While there are still negative correlations for the total and relative amount of body fat in all compartments for serum DHT, there is a statistically yet not significant positive correlation between free testosterone and the central fat distribution in the elderly (mean age 75y) subjects that was not present in their young (mean age 19) counterparts. Moreover, the overall correlation between 17G and central obesity and the 17G/DHT ratio and central obesity raises from 0.08 and 0.20 (p < 0.05) in young men to 0.14 and 0.34 (p < 0.05) in elderly men.

Lean, mean, strong... are these "all things male"?

If we discard the important role of DHT in the brain, which would explain the "mean" (not necessarily defined as mean in aggressive, but rather as "alpha-male mean") in "lean, mean, strong" and expand "strong" to the established bone-building effects of DHT, which apparently surpass those of testosterone (eg. Capur. 1989), being as muscular as Mr. Olympia obviously is not one of the "things male". As, contrary to some of its synthetic cousins, the current research suggests that the original father of all androgens may be an indispensable bystander, when its precursor testosterone is blowing up your muscles, its immediate effects do yet appear to be restricted to strength and body composition.

Collectively, this as well as the previous installments on testosterone (Part 1, Part 2, Part 3) and estrogen should have made it quite clear that even the ostensibly straight forward role of the sex steroids in the concert of skeletal muscle hypertophy is way more complex than the commonly accepted notion that "you just inject your weekly test and become Mr. O" would suggest. It is in fact so complex that I will devote the next installment of the Thoughts to revamp the main ideas and to try to connect the dots between mTOR, myostatin, IGF, inflammation, testosterone, estrogen, DHT and co...

Tuesday, August 23, 2011

Beyond Vida's Book, Part 2/2: Androgen, Progesterone, Estrogen & Corticosteroid Receptor Activities of ALLmost All Anabolic Steroids - Metabolits, Progestins & More

Image 1: Tetrahydrogestrinone aka THG,
aka "The Clear" and the bone of contention
in the "BALCO Scandal" could probably
have been identified years before, if the
WADA detectives already had the new
 mammalian androgen responsive reporter
gene assays at their disposal.
As mentioned in part 1 of this post (cf. Beyond Vida's Book, Part 1/2), Houtman and the other scientists from BioDetection Systems B.V. and the Institute of Public Health and the Environment in the Netherlands, did not exactly want to provide juicers with data on which steroids may cause unexpected side-effects, when they conducted their study in 2008. The original idea was to demonstrate that their technology would be able to identify even those androgens, which have hitherto not been classified as illegal substances - so called "designer steroids", which would not turn up in the chemical–analytical approaches combining gas chromatography (GC) or liquid chromatography (LC) separations with mass spectrometry (MS) or tandem mass spectrometry (MS/MS) simply because their molecular structure is hitherto unknown (you cannot find what you ain't looking for ;-).
This is the second part of a two part series, click here to read more about nandrolone, trenbolone, testosterone and all the androgens on the list of prohibited substances of the World Anti Doping Agency.
If this method had been available back in the day, when Patrick Arnold developed THG (tetrahydrogestrinone aka "The Clear") for BALCO, the detectives from the World Anti Doping Agency (WADA) would probably have been able to identify Marion Jones and other athletes who used this highly performance-enhancing drug, even before baseball star Berry Bonds blew the whistle in 2001.
Figure 1: Relative potency at the androgen (compared to testosterone), progesterone (compared to progesterone) and estrogen alpha and beta receptors (compared to estrogen) of "The Clear" (THG), trenbolone and nandrolone
(calculated based on data from Houtman. 2008)
Now, more than 10 years later, THG is on the list of WADA prohibited compounds and we know that "The Clear" is 0.25x as androgenic as dihydrotestosterone and 1.15x more androgenic than testosterone. We also know that THG is a powerful progestin, with 91% of the receptor activity of "real" progesterone (trenbolone has 35%), but hardly any translational activity at the level of the estrogen (0.0017% for estrogen-beta) and corticosteroid receptor.
Figure 2: Relative potency (new reference:
progesterone!) of steroids not on the
WADA list at the progesterone receptor
(data calculated base on Houtman. 2008)
A few notes on the graphs: Houtman et al. did not measure the relative potency at the progesterone receptor for all of the "other exogenous androgens". Instead of meshing androgen and progesterone activity into a single graph, I thus decided to seperate the two, because otherwise it would have been difficult to identify which of the steroids actually have "zero" transcriptional activity at the progesterone receptor and which just have not been analyzed by the scientists. Additionally I recalculated the references using testosterone and progesterone instead of DHT and the over-potent progestin ORG2085.

Among the better known other (I am sticking to Houtman et al.'s nomenclature, here) exegenous androgens, the Dutch scientists analyzed, trestolone, or 7a-methyl-19-nor-T (MENT), is certainly the "meanest bitch". It's androgenic activity is almost 10x higher than that testosterone (and thus 3x more potant than nandrolone!) and its potency as a transcriptional activator at the level of the progesterone receptor is still 29% of that of progesterone and thus more than 9x higher than that of nandrolone aka "Deca".

Figure 2: Relative potency at of steroids
not on the WADA list at the androgen
receptor; note that I re-calculated the
values relative to testosterone as a new
reference
, this means that you have to
divide the values by 4.68 to get DHT as
a reference, as in Part 1, fig. 2 (data
calculated base on Houtman. 2008)
The major offenders, as far as chances of immediate (cf. red box in part 1 of this article) progesterone-related side effects are concerned, are yet the norethisterone derivatives (relative potencies compared to progesteron)
  1. 11b-ethynyl-NET - 880%
  2. delta-15-NET - 290%
  3. 11b-ethenyl-NET - 262%
  4. 6a-methyl-NET - 253%
  5. 11b-I37ethyl-NET - 139%
I guess, you probably already suspect that these are agents in progesterone-only or combined contraceptive pills. So, in essence nothing athletes will be using.

The 7-alpha-methylated derivate of the progestin nethisterone, 7a-methyl-NET, however, has an androgen/progesterone activity ratio of 427/8. Now, although the respective values for trenbolone and nandrolone are only 442/35 and 327/7 this does not necessarily go to tell you that it would make a powerful mass builder, especially in view of the results of previous studies using CHO-AR reporter gene assays, according to which nandrolone (I do not have data on trenbolone, here) has a 1.6x higher androgen receptor binding affinity than the aforementioned nethisterone derivate.
Image 2: The dissection of the
prostate (image by Gray. 2005) is
an unsavory, yet obligatory part
of the Hershberger assay, an in-
vivo method to evaluate the
androgenic activity of steroids
that was developed by
T.V. Hershberger in the 1960s.
Different tests, different results: Most of the data you will currently find on message-boards and certain webpages is based on the "old" CHO-AR reporter gene assays, the results of which often contradict relative activity levels measured by AR CALUX. According to the CHO-AR gene assay, for example the nandrolone would be the more potent androgen receptor agonist (2.65x more potent, Sonneveld. 2005). According to the Chemical Activated Luciferase gene eXpression test, on the other hand, its almost the other way around. Lastly, according to the good old Hershberger-test, which was developed in the 1960 and '70s as an in-vivo procedure to evaluate the androgenic activity of steroids in rats, 7a-methyl-NET has 6.25x the androgenic activity of nandrolone. While it is likely that the CALUX assay is the most reliable method, when it comes to the exact cellular mechanisms, the good old Hershberger-tests, Julius Vida (the "Vida" from "Vida's Book") used, as well, still have their merit, as they provide some insight into what may happen when the compound is administered to an actual living organism.
Similar to the WADA-prohibited compounds, where with the exception of 4-chloro-19-nor-T, 19-norclostebol (4%) and 19-nor-androstenediol (1%) most of the compounds that have been tested exhibited &lt;1% of the receptor activity of estradiol at both the estrogen beta and alpha receptors, compared to estradiol none of the tested (estrogen receptor transcriptional activity was measured for only 10 out of 36 androgens) compounds had significant estrogenic activity. 7a-methyl-NET, the progestin discussed in the previous paragraph, for example has a relative potency of 0.038%, which is more than 4x higher than the 0.009% potency of nandrolone, yet still less than half of the activity of DHEA (0.081%).
Figure 3: Relative potency of steroid metabolits at the androgen receptor, note that I re-calculated the values relative to testosterone as a new reference, this means that you have to divide the values by 4.68 to get DHT as a reference, as in Part 1, fig. 2 (data calculated base on Houtman. 2008)
Similarly, out of the less-androgenic (cf. figure 3) metabolites and isomers Houtman et al. actually tested, only 5a-androstane-3b,17b-diol (0.543%) and 4-androstenediol (4-AD) (0.125%) presented significant interactions with the estrogen beta receptor (0.039% and 0.012% at the alpha receptor).

If I may remind you of the the high transcriptional activity of nandrolone and trenbolone, I've discussed in the first part of this article, which corresponds well with the progesterone related side-effects many athletes complain about, the relatively high activity of 4-AD at the estrogen receptor (25x higher than testosterone) in the CALUX assay is yet another sign for the real-world relevance of the luciferase assay data (cf. red box "Different tests, different results"). After all, androst-4-ene-3b,17b-diol, which happens to be one of the pro-hormones that has lately re-appeared on the "supplement" market, is well-known to be one of the "wetter" compounds.
Figure 4: Relative potency of several natural and synthetic steroids at the corticosteroid receptor with cortisol as a reference (data calculated based on Houtman. 2008)

Finally, we will have a brief look at those steroids which mess with the glucocorticoid receptor. Other than the usual suspects in figure 4, only fluoxymesterone (0.27%), 5a-hydrogen-11b-methyl-NET (0.52%), 11b-methyl-19-nor-T (1.97%), 7a-methyl-19-nor-T aka "Trestolone" or "MENT" (1.56%) and progesterone (0.65%) exhibit any notable corticosteroid activity (expressed relative to the potency of cortisol). However, nandrolone, trenbolone and other anabolics with progestational activity appear to exert indirect effects on the mammalian corticosteroid metabolism (Moor. 1971) and may thus induce downstream effects the CALUX assay obviously cannot detect (suggested read: red box on DHEA and aromatization in part 1 of this article).

With the issue of literal "side-effects", i.e. effects not related to direct transcriptional activity at the receptor sites, I want to conclude this two part series on the immediate effects of a broad range of androgens on androgen, progesterone, estrogen and corticosteroid receptors by reminding you of the fact that despite an ever-increasing accuracy and the constant development of even more sophisticated analytical methods, there still is (and probably never will be) a machine, where you insert a certain molecule, press a few buttons and get a print out that says: "Person A; age: 25, sex: male; training: 5x a week; nutrition: [...] will gain Xlbs of lean mass and shed Ylbs of fat on a Z-week cycle of XYZmg of compound ALPHA".

Monday, August 22, 2011

Beyond Vida's Book, Part 1/2: Androgen, Progesterone, Estrogen & Corticosteroid Receptor Activities of ALLmost All Anabolic Steroids - WADA Prohibited Compounds.

Image 1: Data on the interaction of androgens
with the progesterone receptor is scarce,
this study has it!
This is only blogpost #499, yet at the same time, its a premiere! It's the first time that I am aware of that something you read at the SuppVersity has been covered by the "competition" before. Kudos to my dutch friends from ergogenics.org, who dug up a 2008 paper by Corine J. Houtman et al. (Houtman. 2008) with extensive CALUX(R) bioassay data on the androgen, progesterone, estrogen and corticosteroid receptor response to allmost all popular steroids - it would probable be the "A", as in 4-androstenediol (the "good old 4-AD"), to "Z", if there actually was a common androgen with a "z" as its first character.
Note! Due to the fact that the sheer amount of data from this study exceeds the time I can spend on analyzing and compiling it for you, today, this is going to be a two part series, with the second part on what the authors describe as "potential" AAS (among these are such illustrious names as 7a-methyl-19-nor-T aka Trestolone or MENT) will follow tomorrow. And don't get mad at me for that, at least it does have the advantage that you can comment / pose questions today and have them answered in detail, by tomorrow ;-)
The original intention of the study obviously was to demonstrate that by the means of the mammalian androgen receptor responsive reporter gene assay (AR CALUX® bioassay), the anti-doping agency would be able to identify hitherto unknown "designer steroids", which would not show up in the usual tests, where the chemical structure of the substance you are looking for must be known beforehand. The CALUX bioassay, on the other hand, directly measures the transcriptional activity of a specific steroid receptor when it is exposed to a given substance and is thus a very reliable measure of the biological effect a certain anabolic will have on the cellular level.
Figure 1: Enzymes, their cellular location,
substrates and products in human
steroidogenesis
; DHEA is the first
compound in the left androgen column
(figure by Slashme and Mikael Häggström)
While it is of course grandiose to be able to measure receptor activity directly, a non-negligible weakness of these bioassays is that they do not provide any insight into the effects of downstream-metabolits of the tested androgen. Let's take dehydroepiteandrosterone (DHEA) as an example. It is well known that after several enzymatic reactions DHEA can eventually be converted to estrogen (cf. figure 1), if however you measure the transcriptional activity of DHEA at the estrogen receptor it turns out to be 0.0813% of 17β-Estradiol (E2). This example clearly shows that, at least in the case of aromatizeable steroids such as DHEA, CALUX provides only part of the overall picture. Keep that in mind, when you are trying to interpret the data!
Other than "Vida" in his famous rat studies, these assays obviously do not provide any information about the "anabolic" value of the respective compounds. Oxandrolone, for example, is known as a highly anabolic steroid, which has about 6x the anabolic activity of testosterone. Nevertheless, its activity at the androgen receptor is only 1% of that of dihydro-testosterone (DHT) and thus no more than 1/20 of the androgen receptor activity of testosterone (cf. figure 2). Accordingly, the following data will not really tell you how much muscle an athlete will be able to accrue whilst taking a certain steroid, but rather which androgen, progesterone, and estrogen related side-effects he or she may experience in the course of that cycle.

Figure 2: Relative potency at the
androgen (reference: DHT) and
progesterone (reference: ORG2085)
receptor of androgens that are
officially prohibited by WADA
(based on Houtman. 2008)
If you have a look at the androgens from the WADA's list of prohibited compounds in figure 2, you will notice that compared to the synthetic progestin 16a-ethyl-21-hydroxy-19nor-4-pregnene-3,20-dione (ORG2085) only a handful of compounds exhibits a significant transcriptional activity at the progesterone receptor:
  • 17a-ethyl-19-nor-T (norethandrolone) - 24%
  • norbolethone - 21%
  • tetrahydrogestrinone (THG) - 7%
  • gestrinone - 5%
  • 17b-trenbolone - 3%
If the occurrence of trenbolone as the last item on the list of androgens with a high activity at the level of the progesterone receptor puzzled you, you obviously have not heard of the dreaded "progestin-gyno" this powerful steroid is supposed to induce!? While 3% of the activity of a synthetic progestin does not sound much, trenbolone is a 6423x more potent activator of the progesterone receptor than testosterone and it is still 525x more active than nandrolone aka "deca", another of the commonly used mass and strength agents the use of which is rumored to have induced gynecomastia in a non-negligible number of drug using athletes.

Only 4-chloro-19-nor-T, 19-norclostebol (4%), 19-nor-androstenediol and methyl-androstenediol (0.1%) exhibit transcriptional activity >0.1% of that elicited by estradiol at the estrogen alpha and beta receptors and none of the tested androgens from the WADA list has an activity >0.002% (this is fluoxymesterone) of that of dexamethasone at the corticosteroid receptor. In order not to overcomplicate things, I have decided to exclude this additional data from figure 2.
This is only part 1! Don't forget to check back tomorrow for more information on metabolites and isomers, such as 4AD & Co., other exogenous androgens that are not yet on the WADA anti-doping list, such as 7a-methyl-19-nor-T (Trestolone,  MENT) and other steroids!

Wednesday, December 8, 2010

Viscous Circle: Low Testosterone > Increased Visceral Fat > Insulin Resistance > Even Lower Testosterone

E.J. Hamilton and colleges (Hamilton. 2010) investigated the effect of androgen deprivation therapy (ADT) in prostate cancer patients on subcutaneous and visceral fat. There results are far from being surprising:
Twelve months ADT increased visceral abdominal fat area by 22% (from 160.8 ± 61.7 to 195.9 ± 69.7 cm2; p<0.01) and subcutaneous abdominal fat area by 13% (from 240.7 ± 107.5 to 271.3 ± 92.8 cm2; p<0.01). Fat mass increased by 14% (+3.4 kg; p<0.001) and lean tissue mass decreased by 3.6% (-1.9 kg; p<0.001). Insulin resistance (HOMA-IR) increased by 12% (2.50 ± 1.12 to 2.79 ± 1.31, p<0.05).
All that by itself is bad enough, but in the end, by the medical suppression of androgens doctors put their poor patients in a viscous circle, from which it will be very difficult to escape, as obesity and insulin resistance will further reduce testosterone production and overall metabolic health regardless of whether they are secondary to low testosterone, come from bad eating habits or whatever.